Dr. Remya Sudevan
Amrita Institute of Medical Sciences, Kochi,India
Title: Use of cardiovascular drugs in the compliance of secondary prevention of coronary artery disease- Hospital based multicentric cross sectional survey
Biography
Biography: Dr. Remya Sudevan
Abstract
Among the mandatory targets to be achieved in the compliance of secondary prevention of coronary artery disease, cardiovascular drug use has a pivotal role. There exists scarcity of data regarding the use of these drugs in coronary artery disease (CAD) patients from resource limited settings. Existing guidelines recommend drug therapy using antiplatelet, lipid lowering drugs, renin angiotensin aldosterone system inhibitors, betablockers, insulin and oral hypoglycaemic agents in diabetics for secondary prevention of CAD. A multi centric hospital based cross sectional survey was done in a total of 1206 patients with confirmed CAD diagnosed during the time period January 2012-December 2018.The objective was to estimate the proportion of compliance to use of cardiovascular drugs. The mean age of the study population was 61.27(9.59) years. In the study population, 879(72.9%) were male patients. The socio economic status was predominantly in the middle (48.1%) and low (48.9%) levels. In the study population, 43% had a family history of heart attack, 64.2% had hypertension, 54.1% had diabetes mellitus, 52% had dyslipidemia, 5.8% had smoking/use of tobacco and 2.8% consumed alcohol. The treatment strategies adopted were medical therapy (44.8%), angioplasty (47.8%) and coronary artery bypass grafting (12.9%). The proportion of patients on cardiovascular drugs were 96.02% on antiplatelets, 89.4% statins, 37.72% on RAAS, 68.2% on betablockers, 22% on insulin and 81.28% on oral hypoglycaemic agents(Table 1). Use of cardiovascular drugs in secondary prevention of CAD patients in resource limited setting appears to be satisfactory.